Episode Details
Back to Episodes
FDA Clears Rein Therapeutics to Resume IPF Trial | Rein Therapeutics (RNTX) | The Watchlist E34
Description
In this episode, listeners hear from Brian Windsor, CEO of Rein Therapeutics (NASDAQ: RNTX), about the FDA’s recent clearance to resume the U.S. Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF). This milestone marks a critical step forward in the company’s respiratory pipeline and offers insight into Rein’s innovative approach to treating fibrotic lung diseases.
This discussion covers:
FDA clearance and the resumption of the U.S. Phase 2 trial of LTI-03
Overview of Rein Therapeutics’ focus on IPF and other fibrotic lung diseases
LTI-03’s unique mechanism leveraging Caveolin-1 to protect lung repair cells
How Rein differentiates itself from other biotech competitors
Next steps for clinical development and the potential market impact
Website: https://reintx.com
This podcast is made in partnership with Rein Therapeutics. This podcast is for informational purposes only. Please do your own due diligence. For our full disclaimer, visit: https://themarketonline.ca/disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.